Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00523848 · OUTCOME

Time to Disease Progression

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma · Source last updated 2017-02-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Every 3 monthsntil the date of first documented progression or date of death from any cause, whichever came first

Groups in this outcome

VDT: VELCADE, Doxil and Low-dose Thalidomide

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
VDT: VELCADE, Doxil and Low-dose Thalidomide40

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
VDT: VELCADE, Doxil and Low-dose Thalidomide27.8Not reported17.732.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        17.7
        upper Limit
        32.1
        value
        27.8
denoms
  1. counts
    1. group Id
      OG000
      value
      40
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. id
    OG000
    title
    VDT: VELCADE, Doxil and Low-dose Thalidomide
param Type
MEDIAN
reporting Status
POSTED
time Frame
Every 3 monthsntil the date of first documented progression or date of death from any cause, whichever came first
title
Time to Disease Progression
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice